Neurogene Inc. - Common Stock (NQ:NGNE)

29.99 +0.89 (+3.06%)

Streaming Delayed Price Updated: 11:32 AM EDT, Jun 15, 2026 Add to My Watchlist

Price and Volume

Volume	23,637
Open	29.56
Bid (Size)	29.90 (100)
Ask (Size)	30.23 (100)
Prev. Close	29.10
Today's Range	28.91 - 29.99
52wk Range	14.65 - 37.27
Shares Outstanding	42,425,071
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

June 08, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2026

From Neurogene Inc.

Via Business Wire

Performance

YTD	+48.8%	+48.8%
1 Month	+0.6%	+0.6%
3 Month	+39.0%	+39.0%
6 Month	+48.0%	+48.0%
1 Year	+58.1%	+58.1%

More News

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

May 12, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

May 12, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 06, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy

April 28, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

April 20, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 08, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

March 24, 2026

From Neurogene Inc.

Via Business Wire

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

March 11, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 03, 2026

From Neurogene Inc.

Via Business Wire

Which stocks are moving on Friday? ↗

February 27, 2026

Via Chartmill

Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗

February 27, 2026

Via Stocktwits

Wondering what's happening in today's after-hours session? ↗

February 26, 2026

Via Chartmill

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

February 26, 2026

From Neurogene Inc.

Via Business Wire

Neurogene to Participate in Upcoming Investor Conferences

February 05, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 04, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

January 12, 2026

From Neurogene Inc.

Via Business Wire

Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 04, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

November 13, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

November 12, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

November 06, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 05, 2025

From Neurogene Inc.

Via Business Wire

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗

November 04, 2025

Via Benzinga

Frequently Asked Questions

Is Neurogene Inc. - Common Stock publicly traded?

Yes, Neurogene Inc. - Common Stock is publicly traded.

What exchange does Neurogene Inc. - Common Stock trade on?

Neurogene Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Neurogene Inc. - Common Stock?

The ticker symbol for Neurogene Inc. - Common Stock is NGNE on the Nasdaq Stock Market

What is the current price of Neurogene Inc. - Common Stock?

The current price of Neurogene Inc. - Common Stock is 29.99

When was Neurogene Inc. - Common Stock last traded?

The last trade of Neurogene Inc. - Common Stock was at 06/15/26 11:32 AM ET

What is the market capitalization of Neurogene Inc. - Common Stock?

The market capitalization of Neurogene Inc. - Common Stock is 1.27B

How many shares of Neurogene Inc. - Common Stock are outstanding?

Neurogene Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.